单剂量赛尼哌联合新赛斯平预防肾移植急性排斥反应的研究  

Preventive Effect of Simplex Dosage Zenapax in Combination with CsA on Acute Rejection after Kidney Transplantation

作　　者：晏强 眭维国 陈怀周 谢申平 申智中 钱锦涛 

机构地区：[1]解放军181中心医院肾移植科,广西桂林541002

出　　处：《华南国防医学杂志》2006年第1期10-12,共3页Military Medical Journal of South China

摘　　要：目的观察使用单剂量赛尼哌联合环孢素(新赛斯平胶囊)对肾移植术后急性排斥反应的预防作用,并对其安全性进行评估。方法将同期行肾移植的80例病人分为对照组和治疗组各40例,除了治疗组术前使用赛尼哌外,两组病人术后治疗方案相同。结果治疗组6个月内急性排斥反应发生率(7.5%)显著低于对照组(25%),在感染及毒副作用方面两组无显著性差别。结论肾移植术前应用单剂量赛尼哌联合新赛斯平胶囊,能有效预防肾移植术后急性排斥反应发生,且经济、安全有效。Objective To observe the preventive effect of simplex dosage zenapax in combination with CsA on acute rejection after kidney transplantion. Methods A total of 80 renal transplant recipients were divided into both the treatment and control groups of forty cases each. There were no difference in postoperative treatment plan between both the groups, but the simplex dosage zenapax was preoperatively given to each patient of the treatment group and not to each one of the control group. Results Acute rejection rate was significantly lower in the treatment group （7.5%） than that in the control group （25.0%） within 6months （ P 〈 0.05 ）. There were insignificant difference in infection and side effect between both the group. Conclusion It is effective, economical and secure to use simplex dosage zenapax in combination with CsA for the prevention of acute rejection after renal tranplantation.

关 键 词：肾移植 赛尼哌 急性排斥反应 

分 类 号：R617[医药卫生—外科学]